Table 2.

Parameters with statistically significant differences between patients with hearing recovery (complete and significant).

4fPTA	Db	p-value*
V1 (7d)	46.87 (31.56; 58.125)	0.001 (V2-V1)
V2 (30d)	32.5 (15.31; 47.81)	0.001 (V3-V1)
V3 (120d)	31.87 (12.18; 44.06)	0.007 (V3-V2)
WRS	%	p-value*
V1 (7d)	82 (64;95)	0.012 (V2-V1)
V2 (30d)	94 (80;100)	0.002 (V3-V1)
V3 (120d)	96 (89;100)	0.013 (V3-V2)
Peroxide	ng/mL	p-value*
V1 (7d)	15.8 (1.625; 108.22)	0.035 (V2-V1)
V2 (30d)	66.55 (27.22; 159.22)	0.836 (V3-V1)
V3 (120d)	19.2 (1.55; 139.2)	0.501 (V3-V2)
Adiponectin	ng/mL	p-value*
V1 (7d)	556.8 (286.14; 926.77)	0.570 (V2-V1)
V2 (30d)	569.4 (352.35; 926.77)	0.079 (V3-V1)
V3 (120d)	394.95 (240.39; 745.87)	0.026 (V3-V2)
IFN-γ	pg/mL	p-value*
V1 (7d)	18.71 (13.02; 28.30)	0.010 (V2-V1)
V2 (30d)	13.63 (9.98; 21.47)	0.121 (V3-V1)
V3 (120d)	14.26 (12.73; 23.30)	0.301 (V3-V2)
IL-2	pg/mL	p-value*
V1 (7d)	3.61 (1.05; 6.56)	0.031 (V2-V1)
V2 (30d)	1.57 (0.082; 2.975)	0.326 (V3-V1)
V3 (120d)	3.2 (0.8275; 6.04)	0.30 (V3-V2)
IL-5	pg/mL	p-value*
V1 (7d)	41.12 (38.36; 47.18)	0.015 (V2-V1)
V2 (30d)	38.83 (34.38; 44.25)	0.032 (V3-V1)
V3 (120d)	40.67 (35.21; 42.39)	0.127 (V3-V2)
TNF-α	pg/mL	p-value*
V1 (7d)	21.07 (11.31; 39.99)	0.026 (V2-V1)
V2 (30d)	12.4 (5.49; 36.9)	0.001 (V3-V1)
V3 (120d)	3.73 (0.41; 26.69)	0.016 (V3-V2)

n = 16. Data represent medians (interquartile interval 25; 75). *Wilcoxon test between visits. p-values < 0.05 were considered significant.